{
    "id": 13151,
    "fullName": "ALK L1198F",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ALK L1198F lies within the protein kinase domain of the Alk protein (UniProt.org). L1198F confers a gain of function to the Alk protein as demonstrated by increased Alk kinase activity and downstream Pi3k and Mapk pathway activation (PMID: 21596819).",
            "references": [
                {
                    "id": 3790,
                    "pubMedId": 21596819,
                    "title": "Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21596819"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "L1198F",
    "createDate": "10/21/2015",
    "updateDate": "09/06/2018",
    "referenceTranscriptCoordinates": {
        "id": 102061,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29220759G>A",
        "cDna": "c.3592C>T",
        "protein": "p.L1198F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3444,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13325,
                "profileName": "NPM1 - ALK ALK L1198F"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3462,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13325,
                "profileName": "NPM1 - ALK ALK L1198F"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3481,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13325,
                "profileName": "NPM1 - ALK ALK L1198F"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3555,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13325,
                "profileName": "NPM1 - ALK ALK L1198F"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3457,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1198F in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13325,
                "profileName": "NPM1 - ALK ALK L1198F"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3553,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13333,
                "profileName": "NPM1 - ALK ALK F1174V ALK L1198F"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3438,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK1198F were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13333,
                "profileName": "NPM1 - ALK ALK F1174V ALK L1198F"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3461,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13333,
                "profileName": "NPM1 - ALK ALK F1174V ALK L1198F"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3434,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13333,
                "profileName": "NPM1 - ALK ALK F1174V ALK L1198F"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3458,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13333,
                "profileName": "NPM1 - ALK ALK F1174V ALK L1198F"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3482,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13333,
                "profileName": "NPM1 - ALK ALK F1174V ALK L1198F"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14086,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, an ALK-positive non-small cell lung cancer patient harboring ALK C1156Y ALK L1198F developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).",
            "molecularProfile": {
                "id": 21371,
                "profileName": "ALK rearrange ALK C1156Y ALK L1198F"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5673,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with EML4-ALK positive non-small lung cancer initially responded to Xalkori (crizotinib) but developed resistance with the emergence of a secondary ALK mutation C1156Y, and subsequently redeveloped sensitivity to Xalkori (crizotinib) upon the emergence of a second ALK mutation, L1198F arising from resistance to Lorlatinib (PF-06463922) (PMID: 26698910).",
            "molecularProfile": {
                "id": 21372,
                "profileName": "EML4 - ALK ALK C1156Y ALK L1198F"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5676,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21372,
                "profileName": "EML4 - ALK ALK C1156Y ALK L1198F"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5672,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with EML4-ALK positive non-small lung cancer with a secondary Xalkori (critzotinib) resistance mutation C1156Y, responded to Lorlatinib (PF-06463922) but subsequently developed resistance upon the emergence of a second ALK mutation, L1198F (PMID: 26698910; NCT01970865).",
            "molecularProfile": {
                "id": 21372,
                "profileName": "EML4 - ALK ALK C1156Y ALK L1198F"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5679,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21372,
                "profileName": "EML4 - ALK ALK C1156Y ALK L1198F"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5687,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21372,
                "profileName": "EML4 - ALK ALK C1156Y ALK L1198F"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5684,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21372,
                "profileName": "EML4 - ALK ALK C1156Y ALK L1198F"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5688,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ALK C1156Y and ALK L1198F in the context of EML4-ALK were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21372,
                "profileName": "EML4 - ALK ALK C1156Y ALK L1198F"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5686,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21373,
                "profileName": "EML4 - ALK ALK L1198F"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5675,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing L1198F in the context of EML4-ALK in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21373,
                "profileName": "EML4 - ALK ALK L1198F"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5683,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).",
            "molecularProfile": {
                "id": 21373,
                "profileName": "EML4 - ALK ALK L1198F"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                },
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5690,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21373,
                "profileName": "EML4 - ALK ALK L1198F"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5680,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with L1198F had reduced sensitivity to growth inhibition mediated by Lorlatinib (PF-06463922) in comparison to EML4-ALK wild type in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21373,
                "profileName": "EML4 - ALK ALK L1198F"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5692,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21375,
                "profileName": "EML4 - ALK ALK F1174C ALK L1198F"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5700,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition by Alecensa (alectinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21375,
                "profileName": "EML4 - ALK ALK F1174C ALK L1198F"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5698,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21375,
                "profileName": "EML4 - ALK ALK F1174C ALK L1198F"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5694,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21375,
                "profileName": "EML4 - ALK ALK F1174C ALK L1198F"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5696,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21375,
                "profileName": "EML4 - ALK ALK F1174C ALK L1198F"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5703,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, introduction of an additional ALK mutation L1198F in transformed cells expressing ALK L1196M in the context of EML4-ALK reduced resistance to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21376,
                "profileName": "EML4 - ALK ALK L1196M ALK L1198F"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5707,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21376,
                "profileName": "EML4 - ALK ALK L1196M ALK L1198F"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5705,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21376,
                "profileName": "EML4 - ALK ALK L1196M ALK L1198F"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5704,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21376,
                "profileName": "EML4 - ALK ALK L1196M ALK L1198F"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5706,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21376,
                "profileName": "EML4 - ALK ALK L1196M ALK L1198F"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5714,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ALK G1202R in the context of EML4-ALK were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21377,
                "profileName": "EML4 - ALK ALK L1198F ALK G1202R"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5717,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21377,
                "profileName": "EML4 - ALK ALK L1198F ALK G1202R"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5715,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21377,
                "profileName": "EML4 - ALK ALK L1198F ALK G1202R"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5716,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21377,
                "profileName": "EML4 - ALK ALK L1198F ALK G1202R"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5718,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21377,
                "profileName": "EML4 - ALK ALK L1198F ALK G1202R"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5725,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21453,
                "profileName": "EML4 - ALK ALK L1198F ALK G1269A"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5726,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21453,
                "profileName": "EML4 - ALK ALK L1198F ALK G1269A"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5727,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21453,
                "profileName": "EML4 - ALK ALK L1198F ALK G1269A"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5723,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ALK G1269A in the context of EML4-ALK were re-sensitized and became modestly sensitive to Xalkori (crizotinib) with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21453,
                "profileName": "EML4 - ALK ALK L1198F ALK G1269A"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5724,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A and L1198F in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21453,
                "profileName": "EML4 - ALK ALK L1198F ALK G1269A"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14084,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung cancer patient harboring ALK I1171N and L1198F in cis in the context of EML4-ALK demonstrated primary resistance to Lorlatinib (PF-06463922) (PMID: 29650534).",
            "molecularProfile": {
                "id": 29939,
                "profileName": "ALK rearrange ALK I1171N ALK L1198F"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13109,
            "profileName": "ALK rearrange ALK L1198F ALK mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13324,
            "profileName": "ALK L1198F",
            "profileTreatmentApproaches": [
                {
                    "id": 8261,
                    "name": "ALK Inhibitor",
                    "profileName": "ALK L1198F"
                }
            ]
        },
        {
            "id": 13325,
            "profileName": "NPM1 - ALK ALK L1198F",
            "profileTreatmentApproaches": [
                {
                    "id": 16860,
                    "name": "Crizotinib",
                    "profileName": "NPM1 - ALK ALK L1198F"
                }
            ]
        },
        {
            "id": 13333,
            "profileName": "NPM1 - ALK ALK F1174V ALK L1198F",
            "profileTreatmentApproaches": [
                {
                    "id": 16849,
                    "name": "Crizotinib",
                    "profileName": "NPM1 - ALK ALK F1174V ALK L1198F"
                }
            ]
        },
        {
            "id": 21371,
            "profileName": "ALK rearrange ALK C1156Y ALK L1198F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21372,
            "profileName": "EML4 - ALK ALK C1156Y ALK L1198F",
            "profileTreatmentApproaches": [
                {
                    "id": 16770,
                    "name": "Crizotinib",
                    "profileName": "EML4 - ALK ALK C1156Y ALK L1198F"
                }
            ]
        },
        {
            "id": 21373,
            "profileName": "EML4 - ALK ALK L1198F",
            "profileTreatmentApproaches": [
                {
                    "id": 16815,
                    "name": "Brigatinib",
                    "profileName": "EML4 - ALK ALK L1198F"
                },
                {
                    "id": 16816,
                    "name": "Crizotinib",
                    "profileName": "EML4 - ALK ALK L1198F"
                }
            ]
        },
        {
            "id": 21375,
            "profileName": "EML4 - ALK ALK F1174C ALK L1198F",
            "profileTreatmentApproaches": [
                {
                    "id": 16782,
                    "name": "Crizotinib",
                    "profileName": "EML4 - ALK ALK F1174C ALK L1198F"
                }
            ]
        },
        {
            "id": 21376,
            "profileName": "EML4 - ALK ALK L1196M ALK L1198F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21377,
            "profileName": "EML4 - ALK ALK L1198F ALK G1202R",
            "profileTreatmentApproaches": [
                {
                    "id": 16817,
                    "name": "Crizotinib",
                    "profileName": "EML4 - ALK ALK L1198F ALK G1202R"
                }
            ]
        },
        {
            "id": 21453,
            "profileName": "EML4 - ALK ALK L1198F ALK G1269A",
            "profileTreatmentApproaches": [
                {
                    "id": 16818,
                    "name": "Brigatinib",
                    "profileName": "EML4 - ALK ALK L1198F ALK G1269A"
                },
                {
                    "id": 16819,
                    "name": "Crizotinib",
                    "profileName": "EML4 - ALK ALK L1198F ALK G1269A"
                }
            ]
        },
        {
            "id": 29939,
            "profileName": "ALK rearrange ALK I1171N ALK L1198F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31935,
            "profileName": "ALK rearrange ALK L1198F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102061,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29220759G>A",
            "cDna": "c.3592C>T",
            "protein": "p.L1198F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}